WebSep 24, 2024 · Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer cells. Among them, we can find mutations, … The compound cis-[Pt(NH3)2Cl2] was first described by Italian chemist Michele Peyrone in 1845, and known for a long time as Peyrone's salt. The structure was deduced by Alfred Werner in 1893. In 1965, Barnett Rosenberg, Van Camp et al. of Michigan State University discovered that electrolysis of … See more Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer See more Cisplatin interferes with DNA replication, which kills the fastest proliferating cells, which in theory are cancerous. Following administration, one chloride ion is slowly displaced by water … See more Syntheses of cisplatin start from potassium tetrachloroplatinate. Several procedures are available. One obstacle is the facile formation of See more Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. It is used to treat various types of cancers, … See more Cisplatin has a number of side effects that can limit its use: • Nephrotoxicity (kidney damage) is the primary dose … See more Cisplatin is the square planar coordination complex cis-[Pt(NH3)2Cl2]. The prefix cis indicates the cis isomer in which two similar ligands are in adjacent positions. The systematic chemical name of this molecule is cis–diamminedichloroplatinum, where ammine with two … See more Cisplatin has been studied with Auger therapy to increase the therapeutic effects of cisplatin, without increasing normal tissue toxicities. See more

Cisplatin - an overview ScienceDirect Topics

Web8.24.4.3.1 Cisplatin. Cisplatin, a platinum analogue, is an alkylating agent used in combination with other agents to treat a variety of solid malignancies, including lung cancer, head and neck cancer, mesothelioma, ovarian cancer, and bladder cancer. It is also used prior to bone marrow and stem cell transplantation. WebA Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer iplayer university challenge

PRODUCT INFORMATION –CISPLATIN …

WebJul 18, 2024 · Cisplatin Brand name: Platinol-AQ Drug class: Antineoplastic Agents - Platinum-containing Agents VA class: AN900 Chemical name: (SP-4-2)-Diamminedichloroplatinum Molecular formula: Cl 2 H 6 N 2 Pt CAS number: 15663-27-1 Medically reviewed by Drugs.com on Jul 18, 2024. Written by ASHP. Introduction Uses … WebAug 26, 2015 · And so, in 1978, cisplatin was approved by the US Food and Drug Administration for use in cancer patients. This international super-group of … WebCisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. Therefore, identifying … oraya movement inc